Iclusig

Drug - Iclusig [ARIAD Pharmaceuticals, Inc.]

June 2013

Therapeutic area - Cancer

Approval criteria

• Diagnosis of chronic myelogenous leukemia AND
• Trial of imitinib AND
• Trial of dasatinib OR nilotinib

Quantity limit

• 15 mg = 68 tablets
• 45 mg = 34 tablets

Background information

Iclusig is a kinase inhibitor indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.

Questions?

MHCP Provider Call Center 651-431-2700 or 800-366-5411